Febrile seizures are the most common type of convulsions. Medicinal prophylaxis is sometimes used for children at high risk of recurrent febrile seizure. In certain circumstances, conventional drugs such as diazepam and phenobarbital cannot be used and the need for alternative medicines is felt. This study compared the effectiveness of topiramate and diazepam in preventing the risk of recurrent febrile seizure in children under 2 yr old.
Introduction
Febrile seizure is the most common type of convulsion in childhood with the prevalence of 2% -5% among children between the ages of 6 and 60 months (1-3). The prevalence of febrile seizure is higher in some regions (e.g. 9%-10% in Japan versus 14% in the Mariana Islands in Guam) (2).
About 21% of seizure attacks happen before or within 1 h after the onset of seizure management (2). Sometimes a preventive treatment is given to a child with a febrile seizure, owing to the incidence of prolonged seizures, parental anxiety, and the hard-to-access medical centers (6). There are currently 3 major recurrent febrile seizure prevention techniques: (i) daily dose of oral phenobarbital, (ii) daily dose of oral sodium valproate, and (iii) oral diazepam during fever episodes. Each of these methods has its own strengths and weaknesses (7-9).
Phenobarbital is an effective medicine for the prevention of a recurrent febrile seizure when its serum concentration reaches15 µg/mL. The intake of phenobarbital has decreased yearly incidence Concerning the benign nature of febrile seizures in most cases, the main goal of treating such patients is to prevent the incidence of a prolonged In the diazepam group, 3 subjects developed significant drowsiness and 2 subjects developed balance disorder (29.4% in total). In the topiramate group, 4 cases developed mild skin rashes, 4 subjects developed irritability, 2 subjects had fever, and 1 subject developed anorexia (45.8% in total) (P=0.008). In general, a major complication was not observed in any of the patients (Figure 2 ).
Discussion
In our study, none of the patients receiving complications. Despite this, the prevalence of 11%-56% was reported for topiramate complications;
whereas, some of these complications were observed in less than half of our subjects (28) (29) (30) (31) .
In conclusion, despite having mild complications, Hereby, we thank all patients and parents for their cooperation in this study. 
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